American ginseng: Effects on indinavir pharmacokinetics

Information

  • Research Project
  • 7485237
  • ApplicationId
    7485237
  • Core Project Number
    F05AT002031
  • Full Project Number
    5F05AT002031-05
  • Serial Number
    2031
  • FOA Number
    PA-03-50
  • Sub Project Id
  • Project Start Date
    7/1/2004 - 19 years ago
  • Project End Date
    6/30/2009 - 14 years ago
  • Program Officer Name
    HAYES, DEBORAH
  • Budget Start Date
    7/1/2008 - 15 years ago
  • Budget End Date
    6/30/2009 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    5
  • Suffix
  • Award Notice Date
    5/19/2008 - 16 years ago

American ginseng: Effects on indinavir pharmacokinetics

[unreadable] DESCRIPTION (provided by applicant): Botanical compounds are commonly used in the treatment of HIV infection. They are more frequently used as an adjunct to conventional therapy rather than as alternative therapy and are often used together with antiretroviral medications. Drug interactions have been already been encountered with their concurrent use. This research project aims to systematically study the pharmacokinetic and pharmacodynamic interactions between indinavir, a HIV protease inhibitor, and American ginseng (Panax quinquefolius), commonly used by HIV-infected patients. We hypothesize that: 1) ginseng may induce the cytochrome P450 system, decreasing indinavir levels, 2) ginseng will reverse indinavir induced insulin resistance. The research project is designed as a phase I, two-period, multiple dose and single sequence, Iongitudinal pharmacokinetic study in 16 healthy volunteers. Indinavir pharmacokinetic profiles and insulin resistance parameters will be measured without and with concurrent 14 days treatment with American ginseng, which will be subjected to our own independent standardization and quality assurance. We will compare the indinavir area under the curve (AUC), other pharmacokinetic parameters and insulin resistance parameters in the same subjects, with and without concurrent ginseng administration. Further drug interaction and insulin clamp studies are planned. [unreadable] [unreadable]

IC Name
NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE
  • Activity
    F05
  • Administering IC
    AT
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    32000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    213
  • Ed Inst. Type
  • Funding ICs
    NCCAM:32000\
  • Funding Mechanism
  • Study Section
    ZAT1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NATIONAL UNIVERSITY OF SINGAPORE
  • Organization Department
  • Organization DUNS
    059519225
  • Organization City
    SINGAPORE
  • Organization State
  • Organization Country
    SINGAPORE
  • Organization Zip Code
    119077
  • Organization District
    SINGAPORE